{"ModuleTitle": "Company Description", "CompanyName": "Cancer Genetics, Inc.", "Symbol": "CGIX", "Address": "201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD, New Jersey, 07070, United States of America", "Phone": "201.528.9200", "Industry": "Medical Specialities", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "The share numbers throughout this Annual Report on Form 10-K reflect a 1-for-30\r\nreverse stock split that the Company effected October 24, 2019.\r\n\r\nOverview\r\n\r\nCancer Genetics, Inc. (the \"Company\") supports the efforts of the biotechnology\r\nand pharmaceutical industries to develop innovative new drug therapies. Until\r\nthe closing of the Business Disposals (as defined below) in July 2019, the\r\nCompany was an emerging leader in enabling precision medicine in oncology by\r\nproviding multi-disciplinary diagnostic and data solutions, facilitating\r\nindividualized therapies through the Company's diagnostic tests, services and\r\nmolecular markers. Following the Business Disposals, the Company currently has\r\nan extensive set of anti-tumor referenced data based on predictive xenograft and\r\nsyngeneic tumor models from the acquisition of vivoPharm, Pty Ltd.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f05%2f29%2f0001349929-20-000005.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Glenn Miles", "title": "Chief Financial Officer"}, {"name": "John A. Roberts", "title": "President & Chief Executive Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}